grant
Channelopathies of Inflammation
Organization UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAHLocation SALT LAKE CITY, UNITED STATESPosted 10 Jan 2025Deadline 30 Nov 2028
NIHUS FederalResearch GrantFY2025AccelerationAction PotentialsAdipose tissueAnti-Arrhythmia AgentsAnti-Arrhythmia DrugsAnti-ArrhythmicsAnti-Cytokine TherapyAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryArrhythmiaAssayAsystoleB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2BioassayBiological AssayBiophysicsBlood SerumBradycardiaCD126 AntigensCD126 ReceptorCalciumCardiacCardiac ArrestCardiac ArrhythmiaCardiac ChronotropismCardiac Muscle CellsCardiac MyocytesCardiac infarctionCardiocyteCardiovascularCardiovascular Body SystemCardiovascular Organ SystemCardiovascular systemCaviaCell Communication and SignalingCell SignalingChronicClinical ResearchClinical StudyClinical TreatmentClinical TrialsCommon Rat StrainsCoronary ReperfusionDataDefectDevelopmentDietDietary FatsDiseaseDisorderDrug TargetingDrugsEthersExhibitsFDA approvedFatsFatty TissueFatty acid glycerol estersFibrosisFutureGenesGoalsGuinea PigsGuinea Pigs MammalsHPGFHealthHeartHeart ArrestHeart ArrhythmiasHeart Muscle CellsHeart RateHeart VascularHeart failureHeart myocyteHepatocyte-Stimulating FactorHigh Fat DietHigh PrevalenceHumanHybridoma Growth FactorHyperlipemiaHyperlipidemiaIFN-beta 2IFNB2IL-6IL-6 ReceptorsIL-6 inhibitorIL6 ProteinIL6 ReceptorsIL6 inhibitorImmunomodulationImpairmentIn VitroInfarctionInflammationInflammatoryInflammatory Bowel DiseasesInflammatory Bowel DisorderInnovative TherapyInterleukin 6 ReceptorInterleukin ActivationInterleukin-6Interleukin-6 inhibitorInterleukinsIntracellular Communication and SignalingK channelKnock-outKnockoutKnowledgeLifeLinkMGI-2MalignantMalignant - descriptorMeasuresMediatingMedicationMetabolicMethodologyMissionModelingModern ManMolecularMuscle CellsMyeloid Differentiation-Inducing ProteinMyocardial InfarctMyocardial InfarctionMyocardial ReperfusionMyocardiumMyocytesNational Institutes of HealthNon obeseNonobeseObesityOutcomePathologicPatientsPerfusionPericardialPericardial body locationPericarditisPharmaceutical PreparationsPhasePhenotypePlasmacytoma Growth FactorPotassium ChannelPotassium Ion ChannelsPredispositionPublic HealthRatRats MammalsRattusReceptor InhibitionReportingResearchRiskRisk FactorsRisk MarkerRisk ReductionScienceSerumSignal InductionSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSterilitySurfaceSusceptibilityTachyarrhythmiasTestingTherapeuticUnited States National Institutes of HealthVentricle RemodelingVentricularVentricular ArrhythmiaVentricular Cardiac RemodelingVentricular Myocardial RemodelingVentricular RemodelingVentricular TachycardiaWeightadiposeadiposityarmarrhythmic agentbiological signal transductionbiophysical foundationbiophysical principlesbiophysical sciencescardiac failurecardiac functioncardiac infarctcardiac musclecardiac preservationcardiomyocytecirculatory systemclinical developmentclinical interventionclinical therapycoronary attackcoronary infarctcoronary infarctioncorpulencecytokinedensitydevelopmentaldiet-associated obesitydiet-induced obesitydiet-related obesitydietary excessdietary lipiddietsdrug/agentevidence baseexpectationfunction of the heartguinea pig modelheart attackheart functionheart infarctheart infarctionheart muscleheart preservationhigh riskhuman modelimmune modulationimmune regulationimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryin vivoinfarctinflammatory disease of the intestineinflammatory disorder of the intestineinhibit IL-6inhibit IL6inhibit Interleukin-6inhibitorinnovateinnovationinnovativeinterferon beta 2interstitialintestinal autoinflammationloss of functionmodel of humanmyocardial remodelingnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyobese patientspatients with obesitypre-clinicalpreclinicalpreservationpreventpreventingreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskresponserisk predictorrisk predictorsrisk-reducingsterilesuccesssudden cardiac deathtachyrhythmiatelemeteringtherapeutic agent developmenttherapeutic developmenttraffickingtrial regimentrial treatmentweightswhite adipose tissueyellow adipose tissue
Description preview
PROJECT ABSTRACT
Obesity is associated with a higher risk for the development of malignant ventricular tachyarrhythmias (VT),
particularly under conditions of repolarization disorders and QT interval prolonging mechanisms (an
established risk factor for VT), and sometimes tragically transitions to sudden cardiac death. In obesity, excess
dietary…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click